方盛制药(603998.SH)控股子公司获得《药品生产许可证》

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a Drug Production License from the Guangdong Provincial Drug Administration for its subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., allowing it to act as the marketing authorization holder for RuLuGuoLi tablets [1] Group 1 - The acquisition of the Drug Production License will help the company and its subsidiary integrate and allocate production and sales resources [1] - This license is expected to improve capacity utilization and reduce production costs for the company [1] - The short-term impact on the company's performance is not expected to be significant following this license acquisition [1]